/

/

FDA panel rejects first MDMA treatment amid deep concerns about flawed trials

Tue, Jun 4

The FDA panel has rejected the first MDMA treatment for PTSD, citing serious concerns about the quality and reliability of the clinical trials conducted. https://t.co/u2VWCLImzW

5771

Committee members said that while the therapy holds promise for treating PTSD, the trials were poorly designed.

Discover